Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

(HZNP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Horizon Therapeutics Public : Morgan Stanley Adjusts Horizon Therapeutics' Price Target to $135 from $103, Keeps Overweight Rating

08/26/2021 | 11:48am EDT


© MT Newswires 2021
All news about HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
07:56aHORIZON THERAPEUTICS PUBLIC : plc. - Newly Published Data Continue to Support Long-Term Ef..
AQ
10/21HORIZON THERAPEUTICS PUBLIC : Says New Data Backing Thyroid Eye Disease Drug Long-Term Eff..
MT
10/21HORIZON THERAPEUTICS PUBLIC : Newly Published Data Continue to Support Long-Term Efficacy ..
BU
10/21Horizon Therapeutics plc Announces Additional Data Supporting the Long-Term Efficacy of..
CI
10/14HORIZON THERAPEUTICS PUBLIC : plc - New Data Reinforce the Relationship Between B-Cell Dep..
AQ
10/13HORIZON THERAPEUTICS PUBLIC : - New TEPEZZA (teprotumumab-trbw) Data to be Presented at th..
AQ
10/13HORIZON THERAPEUTICS PUBLIC : New Data Reinforce the Relationship Between B-Cell Depletion..
BU
10/13Horizon Therapeutics plc Announces Results from A New Analysis of the UPLIZNA Pivotal P..
CI
10/12HORIZON THERAPEUTICS PUBLIC : New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the..
BU
10/11HORIZON THERAPEUTICS PLC : to Release Third-Quarter 2021 Financial Results and Host Webcas..
BU
More news
Analyst Recommendations on HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
More recommendations
Financials (USD)
Sales 2021 3 118 M - -
Net income 2021 406 M - -
Net Debt 2021 1 069 M - -
P/E ratio 2021 67,7x
Yield 2021 -
Capitalization 26 308 M 26 308 M -
EV / Sales 2021 8,78x
EV / Sales 2022 6,72x
Nbr of Employees 1 695
Free-Float 97,9%
Chart HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Duration : Period :
Horizon Therapeutics Public Limited Company Technical Analysis Chart | HZNP | IE00BQPVQZ61 | MarketScreener
Technical analysis trends HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 116,46 $
Average target price 133,00 $
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Timothy P. Walbert Chairman, President & Chief Executive Officer
Paul W. Hoelscher Chief Financial Officer & Executive Vice President
Jeffrey W. Sherman Chief Medical Officer & Executive Vice President
Jeffrey D. Kent Executive VP-Medical Affairs & Outcomes Research
Karin Rosen Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY59.21%26 308
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
PFIZER, INC.16.27%240 303
NOVO NORDISK A/S56.55%239 079
ELI LILLY AND COMPANY42.84%218 640